Effects of an injectable long-acting formulation of ivermectin on Onchocerca ochengi in zebu cattle

The availability of a safe macrofilaricidal drug would help to accelerate onchocerciasis elimination. A trial was conducted in Cameroon to evaluate the effects of a subcutaneous injectable long-acting formulation of ivermectin (LAFI) on the microfilariae (mf) and adult stages of Onchocerca ochengi. Ten zebu cattle naturally infected with the parasite were injected subcutaneously with either 500 mg (group A, N = 4), or 1000 mg long-acting ivermectin (group B, N = 4) or the vehicle (group C, N = 2). Skin samples were collected from each animal before, and 6, 12, and 24 months after treatment to measure microfilarial densities (MFDs). Nodules excised before, and 6 and 12 months after treatment were examined histologically to assess the adult worms’ viability and reproductive status. Blood samples were collected at pre-determined time-points to obtain pharmacokinetic data. Before treatment, the average O. ochengi MFDs were similar in the three groups. Six months after treatment, all animals in groups A and B were free of skin mf, whereas those in group C still showed high MFDs (mean = 324.5 mf/g). Only one ivermectin-treated animal (belonging to group A) had skin mf 12 months after treatment (0.9 mf/g). At 24 months, another animal in group A showed skin mf (10.0 mf/g). The histologic examination of nodules at 6 and 12 months showed that LAFI was not macrofilaricidal but had a strong effect on embryogenesis. The new LAFI regimen might be an additional tool to accelerate the elimination of human onchocerciasis in specific settings.

[1]  P. Berto,et al.  BEPO®: Bioresorbable diblock mPEG-PDLLA and triblock PDLLA-PEG-PDLLA based in situ forming depots with flexible drug delivery kinetics modulation. , 2020, Journal of controlled release : official journal of the Controlled Release Society.

[2]  J. Archer,et al.  Preclinical development of an oral anti-Wolbachia macrolide drug for the treatment of lymphatic filariasis and onchocerciasis , 2019, Science Translational Medicine.

[3]  D. Ince,et al.  Pharmacokinetics, Safety, and Tolerability of Oxfendazole in Healthy Volunteers: a Randomized, Placebo-Controlled First-in-Human Single-Dose Escalation Study , 2019, Antimicrobial Agents and Chemotherapy.

[4]  A. Hoerauf,et al.  Discovery of ABBV-4083, a novel analog of Tylosin A that has potent anti-Wolbachia and anti-filarial activity , 2019, PLoS neglected tropical diseases.

[5]  A. Lampo,et al.  Preclinical toxicity and pharmacokinetics of a new orally bioavailable flubendazole formulation and the impact for clinical trials and risk/benefit to patients , 2019, PLoS neglected tropical diseases.

[6]  R. Gilman,et al.  Oxfendazole: a promising agent for the treatment and control of helminth infections in humans , 2018, Expert review of anti-infective therapy.

[7]  Sarah A. Stewart,et al.  Implantable Polymeric Drug Delivery Devices: Classification, Manufacture, Materials, and Clinical Applications , 2018, Polymers.

[8]  M. Vaillant,et al.  Single dose moxidectin versus ivermectin for Onchocerca volvulus infection in Ghana, Liberia, and the Democratic Republic of the Congo: a randomised, controlled, double-blind phase 3 trial , 2018, The Lancet.

[9]  J. Keiser,et al.  Efficacy and tolerability of moxidectin alone and in co-administration with albendazole and tribendimidine versus albendazole plus oxantel pamoate against Trichuris trichiura infections: a randomised, non-inferiority, single-blind trial. , 2018, The Lancet. Infectious diseases.

[10]  Junyoung Kim,et al.  Cholera Outbreak due to Raw Seafood Consumption in South Korea, 2016. , 2018, The American journal of tropical medicine and hygiene.

[11]  Gerry Killeen,et al.  Targeting cattle for malaria elimination: marked reduction of Anopheles arabiensis survival for over six months using a slow-release ivermectin implant formulation , 2018, Parasites & Vectors.

[12]  M. Boussinesq,et al.  Alternative treatment strategies to accelerate the elimination of onchocerciasis , 2018, International health.

[13]  A. Wagner,et al.  Hygienic Behaviors and Risks for Ascariasis among College Students in Kabul, Afghanistan. , 2017, The American journal of tropical medicine and hygiene.

[14]  M. Boussinesq,et al.  Macrofilaricidal Efficacy of Repeated Doses of Ivermectin for the Treatment of River Blindness , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  J. McCarthy,et al.  In Vitro Efficacy of Moxidectin versus Ivermectin against Sarcoptes scabiei , 2017, Antimicrobial Agents and Chemotherapy.

[16]  Gabriel Kigen,et al.  Drug-transporter mediated interactions between anthelminthic and antiretroviral drugs across the Caco-2 cell monolayers , 2017, BMC Pharmacology and Toxicology.

[17]  D. Boakye,et al.  Genome-wide analysis of ivermectin response by Onchocerca volvulus reveals that genetic drift and soft selective sweeps contribute to loss of drug sensitivity , 2016, bioRxiv.

[18]  B. Makepeace,et al.  25 Years of the Onchocerca ochengi Model. , 2016, Trends in parasitology.

[19]  Hannah C. Slater,et al.  Oral, ultra–long-lasting drug delivery: Application toward malaria elimination goals , 2016, Science Translational Medicine.

[20]  J. Sutra,et al.  Preclinical Study of Single-Dose Moxidectin, a New Oral Treatment for Scabies: Efficacy, Safety, and Pharmacokinetics Compared to Two-Dose Ivermectin in a Porcine Model , 2016, PLoS neglected tropical diseases.

[21]  C. Nwosu,et al.  Management of Cattle Parasitism and Use of Anthelmintics in Mixed Farming Systems in the Vina Division, Cameroon - , 2016 .

[22]  A. Hoerauf,et al.  Therapeutic Efficacy and Macrofilaricidal Activity of Doxycycline for the Treatment of River Blindness , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  D. Lamontagne,et al.  Operational assessments of Sayana® Press provision in Senegal and Uganda. , 2014, Contraception.

[24]  I. Galeska,et al.  Veterinary Long-Acting Injections and Implants , 2013 .

[25]  T. Nolan,et al.  Macrocyclic lactones in the treatment and control of parasitism in small companion animals. , 2012, Current pharmaceutical biotechnology.

[26]  E. Walker,et al.  Lethal and Sublethal Effects of Avermectin/Milbemycin Parasiticides on the African Malaria Vector, Anopheles arabiensis , 2012, Journal of medical entomology.

[27]  Kevin C. Kobylinski,et al.  Comparative evaluation of systemic drugs for their effects against Anopheles gambiae. , 2012, Acta tropica.

[28]  考德瑞尔特·乔治.  Biodegradable drug delivery compositions , 2011 .

[29]  I. Sutherland,et al.  Anthelmintic resistance in nematode parasites of cattle: a global issue? , 2011, Trends in parasitology.

[30]  M. Alvinerie,et al.  ABC transporter modulation: a strategy to enhance the activity of macrocyclic lactone anthelmintics. , 2008, Trends in parasitology.

[31]  M. Boussinesq,et al.  Effect of single-dose ivermectin on Onchocerca volvulus: a systematic review and meta-analysis. , 2008, The Lancet. Infectious diseases.

[32]  G. Jacobson,et al.  Evaluation of a covered-rod silicone implant containing ivermectin for long-term prevention of heartworm infection in dogs. , 2006, American journal of veterinary research.

[33]  V. Tanya,et al.  Repeated high doses of avermectins cause prolonged sterilisation, but do not kill, Onchocerca ochengi adult worms in African cattle , 2005, Filaria journal.

[34]  N. Opoku,et al.  The co-administration of ivermectin and albendazole - safety, pharmacokinetics and efficacy against Onchocerca volvulus , 2003, Annals of tropical medicine and parasitology.

[35]  K. Lasseter,et al.  Safety, Tolerability, and Pharmacokinetics of Escalating High Doses of Ivermectin in Healthy Adult Subjects , 2002, Journal of clinical pharmacology.

[36]  M. Boussinesq,et al.  Effects of standard and high doses of ivermectin on adult worms of Onchocerca volvulus: a randomised controlled trial , 2002, The Lancet.

[37]  V. Tanya,et al.  Chemoprophylaxis of Onchocerca infections: in a controlled, prospective study ivermectin prevents calves becoming infected with O. ochengi , 1999, Parasitology.

[38]  G. Edwards,et al.  Evaluation of suramin, ivermectin and CGP 20376 in a new macrofilaricidal drug screen, Onchocerca ochengi in African cattle. , 1995, Tropical medicine and parasitology : official organ of Deutsche Tropenmedizinische Gesellschaft and of Deutsche Gesellschaft fur Technische Zusammenarbeit (GTZ).

[39]  A. Renz,et al.  Bovine onchocercosis in north Cameroon. , 1994, Veterinary parasitology.

[40]  G. Schares,et al.  Experimental chemotherapy of filariasis: comparative evaluation of the efficacy of filaricidal compounds in Mastomys coucha infected with Litomosoides carinii, Acanthocheilonema viteae, Brugia malayi and B. pahangi. , 1993, Acta tropica.

[41]  H. Gilles,et al.  The chemotherapy of onchocerciasis. XV. Studies with albendazole. , 1991, Tropical medicine and parasitology : official organ of Deutsche Tropenmedizinische Gesellschaft and of Deutsche Gesellschaft fur Technische Zusammenarbeit.

[42]  D. Büttner,et al.  Histological examination of adult Onchocerca volvulus and comparison with the collagenase technique. , 1988, Tropical medicine and parasitology : official organ of Deutsche Tropenmedizinische Gesellschaft and of Deutsche Gesellschaft fur Technische Zusammenarbeit.

[43]  E. Cupp,et al.  Ivermectin prophylaxis against experimental Onchocerca volvulus infection in chimpanzees. , 1988, The American journal of tropical medicine and hygiene.

[44]  H. Gilles,et al.  The chemotherapy of onchocerciasis VIII Levamisole and its combination with the benzimidazoles. , 1982, Annals of tropical medicine and parasitology.

[45]  O. Bain.  Le genre Onchocerca : hypothèses sur son évolution et clé dichotomique des espèces , 1981 .

[46]  O. Bain.  [The genus Onchocherca : hypothesis on its evolution and a key to the species (author's transl)]. , 1981, Annales de parasitologie humaine et comparee.